Vecuronium bromide for injection is indicated for the patients with myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue).
The injection features Sagent’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
Sagent CEO and chairman of the board Jeffrey Yordon said Vecuronium bromide is currently in short supply in the US and they are pleased to offer customers a source for this important niche product.